Two senior executives quit Ranbaxy
In a sustained churn at Ranbaxy Laboratories, Sanjeev Dani, head of global strategy, corporate and business development, and Rajiv Gulati, president of global pharma business, have quit, people familiar with the matter told ET. This follows a slew of exits at the top management in India and the US after rival drugmaker Sun Pharmaceuticals agreed to acquire Ranbaxy in April. Dani and Gulati were part of the executive management committee, the apex leadership team responsible for running day-to-day operations.
In a sustained churn at Ranbaxy Laboratories, Sanjeev Dani, head of global strategy, corporate and business development, and Rajiv Gulati, president of global pharma business, have quit, people familiar with the matter told ET. This follows a slew of exits at the top management in India and the US after rival drugmaker Sun Pharmaceuticals agreed to acquire Ranbaxy in April. Dani and Gulati were part of the executive management committee, the apex leadership team responsible for running day-to-day operations.
Read the Economic Times news report here.
